Baxter International (BAX)
NYSE:BAX
Want to see BAX full AI Analyst Report?
Earnings Data
Report Date
Jul 23, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.37Last Year’s EPS
0.59Same Quarter Last Year
Based on 12 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call balanced notable operational progress (product launches, improved cash flow, continuous improvement adoption and backorder remediation) and a reiterated full-year framework against meaningful near-term financial headwinds (35% EPS decline, margin compression, Novum shipment hold and supply constraints in injectables). Management emphasized a clear turnaround plan, debt reduction priority and expected second-half recovery, but the first-half results and ongoing risks temper optimism.Company Guidance
Reported Revenue and Organic Growth
Global sales from continuing operations totaled $2.7 billion, up 3% year-over-year on a reported basis and down 1% on an organic basis.
Free Cash Flow Turnaround
First-quarter free cash flow was $76 million versus negative $221 million in Q1 2025, reflecting improved cash generation and working capital efficiency.
Segment Outperformance – Advanced Surgery
Advanced Surgery delivered strong growth with sales of $304 million, up 10% year-over-year, driven by hemostats and sealants and steady procedure volumes.
High Growth in Drug Compounding
Drug compounding grew approximately 20%, contributing to Pharmaceuticals segment growth and reflecting continued strong demand for compounding services.
Product Innovation and New Launches
Launched several new products including Dynamo (smart hospital stretcher), IV Verified Line labeling system, XR spine surgical table, and Connex 360; continued integration of AI in Connected Care Foundation and frontline workflows.
Operational Progress and Continuous Improvement
Rollout of Baxter GPS continuous improvement program: 10 President Kaizen events kicked off and more than 230 continuous improvement events launched; management delayering and P&L accountability pushed to operating leaders.
Backorder Clearance and Manufacturing Throughput
Significant progress made in clearing back orders at a key manufacturing facility and increased throughput, helping stabilize Pharma supply dynamics.
Financial Outlook Reiterated
Management reiterated full-year 2026 guidance: reported sales growth flat to +1%, organic sales roughly flat, adjusted operating margin 13%–14%, and adjusted EPS from continuing operations $1.85–$2.05.
Balance Sheet and Capital Allocation Priorities
Positive free cash flow and focus on working capital support priority of debt paydown with a target net leverage of ~3x by end of 2026; plan to consider tuck-in M&A or share repurchases after deleveraging.
BAX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BAX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 30, 2026 | $16.90 | $17.58 | +4.02% |
Feb 12, 2026 | $22.26 | $18.70 | -15.99% |
Oct 30, 2025 | $22.40 | $19.14 | -14.54% |
Jul 31, 2025 | $27.83 | $21.59 | -22.43% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Baxter International (BAX) report earnings?
Baxter International (BAX) is schdueled to report earning on Jul 23, 2026, Before Open (Confirmed).
What is Baxter International (BAX) earnings time?
Baxter International (BAX) earnings time is at Jul 23, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BAX EPS forecast?
BAX EPS forecast for the fiscal quarter 2026 (Q2) is 0.37.
